Juming Yan

Juming Yan

Auto-generated profile, based on publicly available information

Juming Yan

Jiangsu Key Laboratory of Immunity and Metabolism, Jiangsu International Laboratory of Immunity and Metabolism, Department of Pathogen Biology and Immunology, Xuzhou Medical University, Xuzhou, Jiangsu 221004, China

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2017 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
YGYulong Gao
Yulong Gao
Fernando Souza-Fonseca-GuimaraesFernando Souza-Fonseca-Guimaraes
Fernando Souza-Fonseca-Guimaraes
TBTobias Bald
Tobias Bald
SNSusanna S Ng
Susanna S Ng
AYArabella Young
Arabella Young
MSMark J Smyth
Mark J Smyth

1 January 2020 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
JYJuming Yan
Juming Yan
SAStacey Allen
Stacey Allen
EMElizabeth McDonald
Elizabeth McDonald
IDIndrajit Das
Indrajit Das
JMJeffrey Y. W. Mak
Jeffrey Y. W. Mak
MTMichele W.L. Teng
Michele W.L. Teng
Mucosal-associated invariant T (MAIT) cells are innate-like T cells that require MHC class I–related protein 1 (MR1) for their development. The role of MAIT cells in cancer is unclear, and to date no study has evaluated these cells in vivo in this context. Here, we demonstrated that tumor initiation, growth, and experimental lung metastasis were significantly reduced in Mr1−/− mice, compared with wild-type mice. The antitumor activity observed in Mr1−/− mice required natural killer (NK) and/or CD8+ T cells and IFNγ. Adoptive transfer of MAIT cells into Mr1−/− mice reversed metastasis reduction. Similarly, MR1-blocking antibodies decreased lung metastases and suppressed tumor growth. Following MR1 ligand exposure, some, but not all, mouse and human tumor cell lines upregulated MR1. Pretreatment of tumor cells with the stimulatory ligand 5-OP-RU or inhibitory ligand Ac-6-FP increased or decreased lung metastases, respectively. MR1-deleted tumors resulted in fewer metastases compared with parental tumor cells. MAIT cell suppression of NK-cell effector function was tumor-MR1–dependent and partially required IL17A. Our studies indicate that MAIT cells display tumor-promoting function by suppressing T and/or NK cells and that blocking MR1 may represent a new therapeutic strategy for cancer immunotherapy. Significance: Contradicting the perception that MAIT cells kill tumor cells, here MAIT cells promoted tumor initiation, growth, and metastasis. MR1-expressing tumor cells activated MAIT cells to reduce NK-cell effector function, partly in a host IL17A–dependent manner. MR1-blocking antibodies reduced tumor metastases and growth, and may represent a new class of cancer therapeutics. This article is highlighted in the In This Issue feature, p. 1

2 July 2017 in Cold Spring Harbor Perspectives in Biology
Verified
Journal Article
Open access
PDF file
JYJuming Yan
Juming Yan
MSMark J. Smyth
Mark J. Smyth
MTMichele W.L. Teng
Michele W.L. Teng
The balance of proinflammatory cytokines interleukin (IL)-12 and IL-23 plays a key role in shaping the development of antitumor or protumor immunity. In this review, we discuss the role IL-12 and IL-23 plays in tumor biology from preclinical and clinical data. In particular, we discuss the mechanism by which IL-23 promotes tumor growth and metastases and how the IL-12/IL-23 axis of inflammation can be targeted for cancer therapy.

1 March 2019 in OncoImmunology
Verified
Journal Article
Closed access
JLJing Liu
Jing Liu
JOJake S. O’donnell
Jake S. O’donnell
JYJuming Yan
Juming Yan
JMJason Madore
Jason Madore
SAStacey Allen
Stacey Allen
MTMichele W. L. Teng
Michele W. L. Teng
Adjuvant immunotherapies targeting CTLA4 or PD-1 recently demonstrated efficacy in the treatment of earlier stages of human cancer. We previously demonstrated using mouse spontaneous metastasis models that neoadjuvant immunotherapy and surgery was superior, compared to surgery and adjuvant immunotherapy, in eradicating the lethal metastatic disease. However, the optimal scheduling between neoadjuvant immunotherapy and surgery and how it impacts on efficacy and development of immune-related adverse events (irAEs) remains undefined. Using orthotopic 4T1.2 and E0771 mouse models of spontaneously metastatic mammary cancer, we varied the schedule and duration of neoadjuvant immunotherapies and surgery and examined how it impacted on long-term survival. In two tumor models, we demonstrated that a short duration (4–5 days) between first administration of neoadjuvant immunotherapy and resection of the primary tumor was necessary for optimal efficacy, while extending this duration (10 days) abrogated immunotherapy efficacy. However, efficacy was also lost if neoadjuvant immunotherapy was given too close to surgery (2 days). Interestingly, an additional 4 adjuvant doses of treatment following a standard 2 doses of neoadjuvant immunotherapy, did not significantly improve overall tumor-free survival regardless of the combination treatment (anti-PD-1+anti-CD137 or anti-CTLA4+anti-PD-1). Furthermore, biochemical immune-related adverse events (irAEs) increased in tumor-bearing mice that received the additional adjuvant immunotherapy. Overall, our data suggest that shorter doses of neoadjuvant immunotherapy scheduled close to the time of surgery may optimize effective anti-tumor immunity and reduce severe irAEs.

1 March 2020 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
JYJuming Yan
Juming Yan
XLXian-Yang Li
Xian-Yang Li
AAAmelia Roman Aguilera
Amelia Roman Aguilera
CXChristos Xiao
Christos Xiao
CJCelia Jacoberger-Foissac
Celia Jacoberger-Foissac
MSMark J. Smyth
Mark J. Smyth
Natural killer (NK) cell protection from tumor metastases is a critical feature of the host immune response to cancer, but various immunosuppression mechanisms limit NK cell effector function. The ectoenzyme, CD39, expressed on tumor-infiltrating myeloid cells, granulocytes, and lymphocytes, including NK cells, converts extracellular ATP (eATP) into AMP and, thus, potentially suppresses eATP-mediated proinflammatory responses. A CD39-targeting monoclonal antibody (mAb) that inhibits the mouse ectoenzyme CD39 suppressed experimental and spontaneous metastases in a number of different tumor models and displayed superior antimetastatic activity compared with the CD39 inhibitor POM1 and inhibitors and mAbs that block other members of the adenosinergic family (e.g., A2AR and CD73). The antimetastatic activity of anti-CD39 was NK cell and IFNγ dependent, and anti-CD39 enhanced the percentage and quantity of IFNγ produced and CD107a expression in lung-infiltrating NK cells following tumor challenge and anti-CD39 therapy. Using conditional Cd39 gene–targeted mouse strains and adoptive NK cell transfers, we showed that CD39 expressed on bone marrow–derived myeloid cells was essential for anti-CD39′s antimetastatic activity, but NK cell expression of CD39 was not critical. The eATP receptor P2X7 and the NALP3 inflammasome, including downstream IL18, were critical in the mechanism of action of anti-CD39, and the frequency of P2X7 and CD39 coexpressing lung alveolar macrophages was specifically reduced 1 day after anti-CD39 therapy. The data provide a mechanism of action involving NK cells and myeloid cells, and anti-CD39 combined with anti–PD-1, NK cell–activating cytokines IL15 or IL2, or an inhibitor of A2AR to effectively suppress tumor metastases.

4 October 2014 in Oncotarget
Verified
Journal Article
Open access
PDF file
HZHongyu Zhou
Hongyu Zhou
TSTao Shen
Tao Shen
CSChaowei Shang
Chaowei Shang
YLYan Luo
Yan Luo
LLLei Liu
Lei Liu
Shile HuangShile Huang
Shile Huang
Ciclopirox induces autophagy through reactive oxygen species-mediated activation of JNK signaling pathway Ciclopirox induces autophagy through reactive oxygen species-mediated activation of JNK signaling pathway